Citations

Clear

3138 citation(s) found for "Smith, AM".

Optimizing the Start Time of Statin Therapy for Patients with Diabetes
Denton, Brian T., Kurt, Murat , Shah, Nilay D., Bryant, Sandra C. , Smith, Steven A., Denton, Brian T.

Mayo Clinic

Medical Decision Making | May 8, 2009 | Volume: 29 | Issue: 3 | Pages: 351-367

10.1177/0272989x08329462 | PMID 19429836 Get It

Background . Clinicians often use validated risk models to guide treatment decisions for cardiovascular risk reduction. The most common risk models for predicting cardiovascular risk are the UKPDS, Framingham, and Archimedes models. In this article, the authors propose a model to optimize the selection of patients for statin therapy of hypercholesterolemia, for patients with type 2 diabetes, using each of the risk models. For each model, they evaluate the role of age, gender, and metabolic state on the optimal start time for statins. Method . Using clinical data from the Mayo Clinic electronic medical record, the authors construct a Markov decision process model with health states composed of cardiovascular events and metabolic factors such as total cholesterol and high-density lipoproteins. They use it to evaluate the optimal start time of statin treatment for different combinations of cardiovascular risk models and patient attributes. Results . The authors find that treatment decisions depend on the cardiovascular risk model used and the age, gender, and metabolic state of the patient. Using the UKPDS risk model to estimate the probability of coronary heart disease and stroke events, they find that all white male patients should eventually start statin therapy; however, using Framingham and Archimedes models in place of UKPDS, they find that for male patients at lower risk, it is never optimal to initiate statins. For white female patients, the authors also find some patients for whom it is never optimal to initiate statins. Assuming that age 40 is the earliest possible start time, the authors find that the earliest optimal start times for UKPDS, Framingham, and Archimedes are 50, 46, and 40, respectively, for women. For men, the earliest optimal start times are 40, 40, and 40, respectively. Conclusions . In addition to age, gender, and metabolic state, the choice of cardiovascular risk model influences the apparent optimal time for starting statins in patients with diabetes.
Melloni's Illustrated Review of Human Anatomy, 3rd ed.
Smith, Andrew R. M.

Mayo Clinic

American Journal of Roentgenology | April 21, 2009 | Volume: 192 | Issue: 5 | Pages: W270-W270

10.2214/ajr.08.2050 Get It

Adenovirus Activates Complement by Distinctly Different Mechanisms In Vitro and In Vivo: Indirect Complement Activation by Virions In Vivo
Xu, Zhili , Hofherr, Sean, Barry, Michael A. , Byrnes, Andrew P. , Tian, Jie , Smith, Jeffrey S. , Barry, Michael A

Mayo Clinic

Journal of Virology | March 26, 2009 | Volume: 83 | Issue: 11 | Pages: 5648-5658

10.1128/jvi.00082-09 | PMID 19321608 Get It

ABSTRACTUnderstanding innate immunity is key to improving the safety of adenovirus (Ad) vectors for systemic gene therapy. Ad has been shown to activate complement in vitro, but activation of complement after Ad injection in vivo has not been directly measured. Using complement protein C3a as a marker of complement activation, we show that types 2 and 5 human Ads cause rapid complement activation after intravenous injection in mice. Unexpectedly, the mechanisms in vivo were different than those in vitro. Antibodies were critical for the activation of complement by Ad in vitro, but antibodies were not required in vivo. The classical pathway was required in vitro, whereas complement activation in vivo involved both classical and nonclassical pathways as well as the reticuloendothelial system. Remarkably, the entry-deficient Ad mutantts1 was completely unable to activate complement in vivo even though it was fully able to activate complement in vitro. This result demonstrates that the complement system senses intravenously injected Ad primarily by detecting the effects of Ad on cells rather than through direct interaction of complement with virions. Encouragingly, shielding Ad with polyethylene glycol was effective at reducing complement activation both in vitro and in vivo. In summary, intravenously injected Ad rapidly activates complement through multiple pathways, but these pathways are different than those identified by in vitro studies. In vitro studies are poorly predictive of in vivo mechanisms because Ad virions activate complement through indirect mechanisms in vivo.
Hockey Education Program (HEP): A Statewide Measure of Fair Play, Skill Development, and Coaching Excellence
Smith, Aynsley M., Jorgenson, M. B., Sorenson, Matthew C., Margenau, David, Link, Andrew A., MacMillan, Michael, Stuart, Michael J.

Mayo Clinic

Journal of ASTM International | March 12, 2009 | Volume: 6 | Issue: 4 | Pages: 1-14

10.1520/jai101857 Get It

Abstract Following the death of a youth hockey coach in a fight with a parent in 2000, the Mayo Clinic Sports Medicine Center and Minnesota Hockey collaborated to implement a three-component Hockey Education Program (HEP). HEP was initiated in 2003 to ensure youth players develop sportsmanship, skills, and a Fair Play approach to the game. Another goal was to decrease attrition of players, coaches, and officials. Coaching Excellence, a component of HEP, is based on 25 years of youth sport research. The HEP manuals Coaches Who Never Lose and Sports and Your Child contain the philosophy, objectives, and guidelines to ensure implementation of HEP components across players, coaches, and parents. The Skill Development component emphasizes learning age-appropriate hockey skills though skill progression. Increasing the practice-to-game ratio to 3–4 practices per game greatly increases the maximum time players skate with the puck during developmental years. Pre- and post-season Skills Challenges allow coaches, players, and parents to gauge improvement, and structure practices to address identified skill deficits. The Fair Play (FP) component emphasizes sportsmanship. Teams earn a FP point each game if they incur less than a preset number of penalty minutes. A coach receiving a game misconduct or a parent/spectator asked to leave the game will cause the team to forfeit their FP point. FP points are factored into league standings across the state. This past season, 17 678 records of game data were obtained and 25 % (4420) were randomly selected for analysis. The data analysis permits comparison across seasons and changes are made accordingly. Based on four years of data, most Minnesota youth hockey games are played in a sportsmanlike manner. Checking from behind and head contact penalties have decreased since the penalty minutes for these dangerous infractions were increased.
Treatment of Bowler's Neuroma with Digital Nerve Translocation
Swanson, Scott J. , Macias, Luis H., Smith, Anthony A.

Mayo Clinic

HAND | February 11, 2009 | Volume: 4 | Issue: 3 | Pages: 323-326

10.1007/s11552-009-9170-2 | PMID 19214641 Get It

Bowler's thumb presents as paresthesias or a neuroma involving the ulnar digital nerve of the thumb. Over 95 million people enjoy bowling worldwide with nearly 3 million certified league bowlers in the United States. While the incidence of Bowler's thumb is unknown, it is an unrelenting nuisance for bowlers, and symptoms can be severe enough to prevent further sport participation. The condition can be managed nonoperatively with rest and splinting, but successful nonoperative treatment frequently requires discontinuation of bowling. The pressure on athletes to resume sports participation sooner and the possibility of nonoperative treatment failure mandate the need for development of a dependable surgical procedure for this condition. We present a case report of a successful surgical treatment by transposing the ulnar digital nerve dorsal to the adductor pollicis. The patient returned to manual labor and resumed bowling and is symptom free 3 years postsurgery.
CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity
Ko, Han Seok , Bailey, Rachel M. , Smith, Wanli W. , Liu, Zhaohui , Shin, Joo‐Ho , Lee, Yun-Il, Zhang, Yong‐Jie , Jiang, Haibing , Ross, Christopher A. , Moore, Darren J. , Patterson, Cam, Petrucelli, Leonard , Dawson, Ted M. , Dawson, Valina L. , Zhang, Yong-Jie , Ross, Christopher A , Dawson, Valina L

Mayo Clinic

Proceedings of the National Academy of Sciences | February 7, 2009 | Volume: 106 | Issue: 8 | Pages: 2897-2902

10.1073/pnas.0810123106 | PMID 19196961 Get It

Mutation in leucine-rich repeat kinase-2 ( LRRK2 ) is the most common cause of late-onset Parkinson's disease (PD). Although most cases of PD are sporadic, some are inherited, including those caused by LRRK2 mutations. Because these mutations may be associated with a toxic gain of function, controlling the expression of LRRK2 may decrease its cytotoxicity. Here we show that the carboxyl terminus of HSP70-interacting protein (CHIP) binds, ubiquitinates, and promotes the ubiquitin proteasomal degradation of LRRK2. Overexpression of CHIP protects against and knockdown of CHIP exacerbates toxicity mediated by mutant LRRK2. Moreover, HSP90 forms a complex with LRRK2, and inhibition of HSP90 chaperone activity by 17AAG leads to proteasomal degradation of LRRK2, resulting in increased cell viability. Thus, increasing CHIP E3 ligase activity and blocking HSP90 chaperone activity can prevent the deleterious effects of LRRK2. These findings point to potential treatment options for LRRK2-associated PD.
Technique of Laparoscopic Ventral Hernia Repair Can Be Modified to Successfully Repair Large Defects in Patients With Loss of Domain
Baghai, Mercedeh, Ramshaw, Bruce , Smith, C. Daniel, Fearing, Nicole, Bachman, Sharon L., Ramaswamy, Archana

Mayo Clinic

Surgical Innovation | January 22, 2009 | Volume: 16 | Issue: 1 | Pages: 38-45

10.1177/1553350608331226 | PMID 19164414 Get It

Background. Laparoscopic ventral hernia repair (LVHR) can be challenging in patients with large abdominal wall defects and loss of domain (LOD). When hernia contents are reduced, the pneumoperitoneum preferentially fills the sac, leaving no space for mesh manipulation. This study presents a modification for LVHR in LOD patients, as well as outcomes for a series of patients. Methods. Between September 2002 and August 2004, 10 patients with large ventral hernias and LOD underwent attempts at LVHR. The technique is modified by placing additional trocars to allow for fixation from above the mesh. Patient data were harvested from a prospective database and analyzed. Results. All hernias were recurrent in nature. Mean defect size was 626 cm 2 , requiring 1 to 4 pieces of sutured Gore Dualmesh for a tension-free repair. Three patients' procedures were aborted after adhesiolysis, with concerns about missed enterotomies. All 3 underwent delayed mesh placement within the same hospitalization. Only 2 were successful. The third patient had significant bowel edema precluding mesh placement. Two patients were converted to open repairs (Rives—Stoppa and component separation). There were no mortalities, but there were 2 major complications: inferior vena cava thrombosis and transient abdominal compartment syndrome. In follow-up (7.7 months) there were 2 recurrences secondary to excision of infected mesh. Conclusion. It is possible to obtain a successful LVHR in patients with large defects and LOD. The technique is complex and is modified to allow for mesh fixation from above the mesh. Frequent change in patient positioning allows for visualization below the fascial defect.
A Synthesis of the World Literature of Ice Hockey Injuries: Epidemiologic Principles and Future Directions
Dajani, K. A., Crawford, B, Gill, Martin , Link, Andrew A., Smith, Aynsley M., Stuart, Michael J.

Mayo Clinic

Journal of ASTM International | December 30, 2008 | Volume: 5 | Issue: 10 | Pages: 1-45

10.1520/jai101778 Get It

Abstract Ice hockey is a fast-paced, aggressive sport whose participants are subject to relatively high rates of injury. Although there is a growing emphasis on the epidemiology of ice hockey research and its application towards reducing injuries, the literature has never been organized into an accessible database. Ice hockey is played in North America, Europe, Scandinavia, the U.K., and several other non-English speaking countries, yet injury reports not written in English are often ignored in review articles. The purpose of this project was to synthesize the existing world literature on ice hockey injuries into a framework of epidemiologic criteria, accessible in an organized, retrievable library. An extensive search of the following databases was done: MEDLINE, BIOSIS, EMBASE, NTIS, CURRENT CONTENTS, DISSERTATION ABSTRACTS, SPORT DISCUS, CINAHL, and WEB OF SCIENCE. Key words used were “ice hockey” and “injuries,” and the search range was 1966 to July 2007. Endnote X (Thompson Corp., Stamford, CT) was used for reference compilation. Eight hundred sixty seven documents were catalogued, from 27 countries in 8 languages. Documents were first categorized by type, including injury (226), equipment (45), case reports (94), review articles (294), editorials (39), or as focusing on the physiological, psychological, or medical aspects of ice hockey (169). Documents were then subdivided by study type and whether they were prospective (117) or retrospective (109). Further subdivisions beyond these levels were based on the inclusion of certain critical epidemiological criteria, including exposure time, a clear definition of “injury,” and the level of play, among others. This comprehensive database should make future ice hockey research more efficient, as well as promote sound epidemiology and a more global perspective.
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
Karp, Judith E. , Flatten, Karen S., Feldman, Eric J. , Greer, Jacqueline M., Loegering, David A., Ricklis, Rebecca M., Morris, Lawrence E. , Ritchie, Ellen K. , Ironside, Valerie, Talbott, Timothy M., Le, Son B. , Meng, Xue , Schneider, Paula A., Dai, Nga T., Adjei, Alex A. , Gore, Steven D. , Wright, John J., Smith, B. Douglas , Roboz, Gail J. , Levis, Mark J. , Wright, John J., Garrett‐Mayer, Elizabeth , Kaufmann, Scott H.

Mayo Clinic

Blood | December 24, 2008 | Volume: 113 | Issue: 20 | Pages: 4841-4852

10.1182/blood-2008-08-172726 | PMID 19109557 Get It

Abstract The farnesyltransferase inhibitor tipifarnib exhibits modest activity against acute myelogenous leukemia. To build on these results, we examined the effect of combining tipifarnib with other agents. Tipifarnib inhibited signaling downstream of the farnesylated small G protein Rheb and synergistically enhanced etoposide-induced antiproliferative effects in lymphohematopoietic cell lines and acute myelogenous leukemia isolates. We subsequently conducted a phase 1 trial of tipifarnib plus etoposide in adults over 70 years of age who were not candidates for conventional therapy. A total of 84 patients (median age, 77 years) received 224 cycles of oral tipifarnib (300-600 mg twice daily for 14 or 21 days) plus oral etoposide (100-200 mg daily on days 1-3 and 8-10). Dose-limiting toxicities occurred with 21-day tipifarnib. Complete remissions were achieved in 16 of 54 (30%) receiving 14-day tipifarnib versus 5 of 30 (17%) receiving 21-day tipifarnib. Complete remissions occurred in 50% of two 14-day tipifarnib cohorts: 3A (tipifarnib 600, etoposide 100) and 8A (tipifarnib 400, etoposide 200). In vivo, tipifarnib plus etoposide decreased ribosomal S6 protein phosphorylation and increased histone H2AX phosphorylation and apoptosis. Tipifarnib plus etoposide is a promising orally bioavailable regimen that warrants further evaluation in elderly adults who are not candidates for conventional induction chemotherapy. These clinical studies are registered at www.clinicaltrials.gov as #NCT00112853.
Phase I Versus Palliative Care: Striking the Right Balance
Schapira, Lidia , Moynihan, Timothy J. , Gunten, Charles F. von , Smith, Thomas J. , Smith, Thomas J

Mayo Clinic

Journal of Clinical Oncology | December 9, 2008 | Volume: 27 | Issue: 2 | Pages: 307-308

10.1200/jco.2008.20.7803 | PMID 19064948 Get It